<DOC>
	<DOCNO>NCT00150969</DOCNO>
	<brief_summary>The purpose study determine whether supplementation 5 mg vitamin K daily 2-year period prevent bone loss post-menopausal woman osteopenia .</brief_summary>
	<brief_title>Vitamin K Supplementation Post-Menopausal Osteopenia</brief_title>
	<detailed_description>Osteoporosis major cause morbidity mortality Canadian postmenopausal woman . It systemic disease characterize low bone mass deterioration bone microarchitecture , result bone fragility increase risk fracture . One six woman age 50 osteoporosis . The lifetime risk osteoporotic fracture average 50 year-old Canadian woman &gt; 40 % . The annual health care cost osteoporotic fracture Canada estimate exceed $ 1.3 billion . Recent data suggest vitamin K supplement may decrease bone loss prevent fracture . Vitamin K co-factor gamma-glutamyl carboxylase , enzyme catalyze gamma-carboxylation glutamic acid residue bone matrix protein osteocalcin . Vitamin K report enhance bone formation vitro study vivo study animal . Vitamin K level low individual osteoporosis patient osteoporotic fracture . The study examine vitamin K supplementation human show promising result significant side effect , study significant methodological shortcoming inadequate sample size lack randomization . The primary objective study examine whether vitamin K supplementation increase bone mineral density postmenopausal woman osteopenia . Our secondary objective examine possible adverse effect long-term vitamin K supplementation , investigate whether vitamin K decrease risk fracture determine vitamin K affect quality life . Our hypothesis vitamin K increase bone mineral density postmenopausal woman , significant adverse effect vitamin K supplementation .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<criteria>Postmenopausal : One year since natural cessation menses , Hysterectomy either postmenopausal status confirm FSH lab value , age 55 AND 2 . Osteopenic : Tscore baseline ( include ) 1.0 2.0 lumbar spine ( L1L4 ) , total hip femoral neck , low reading three measurement must 1.0 2.0 1 . Women ever fragility fracture age 40 ; 2 . Women currently anticoagulant , previously anticoagulant past 3 month , expect anticoagulant near future ; 3 . Women hormone replacement therapy , raloxifene , bisphosphonates calcitonin past 3 month ; 4 . Women ever bisphosphonate 6 month ; 5 . Women previously diagnose Paget 's disease , hyperparathyroidism , hyperthyroidism metabolic bone disease ; 6 . Women decompensated disease liver , kidney , pancreas , lung , heart ; 7 . Women history active cancer past 5 year ; 8 . Women take megadoses vitamin A ( 10,000 iu per day ) E ( 400 iu per day ) ; 9 . Women involve clinical trial ; 10 . Any woman , opinion principal investigator , poor medical psychiatric risk study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>vitamin K</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>post-menopausal woman</keyword>
	<keyword>randomize double blind placebo control trial</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>woman 's health</keyword>
</DOC>